|
목적 : To assess the efficacy and safety of intravitreal dexamethasone implant injection in the management of sarcoidosis-related uveitis.
방법 : In this study, retrospective analysis of efficacy and safety of intravitreal dexamethasone implant injection for various indications such as intractable vitritis, vasculitis, cystoid macular edema, or before cataract surgery were performed. This study included 20 sarcoidosis-related uveitis patients.
결과 : The BCVA showed significant improvement at 1-month (P=.004) and 3-months (P=.001) after treatment, but there was no significance at 6-months after treatment(P=.186). One month after intravitreal dexamethasone implant injection, the central macular thickness (CMT) decreased to 278.95±52.20 μm (P=.023). The CMT further decreased to 274.70±55.88 (at 3-months, P=.074) and 280.65±64.48 (at 6-months after treatment, P=.354).The anterior chamber cell grade (P=.003) and vitreous haze (P=.001) were significantly decreased up to 6-months after a single intravitreal dexamethasone implant injection.
결론 : Intravitreal dexamethasone implant injection is efficacious in reducing the anterior chamber inflammation, vitreous haze, and cystoid macular edema in sarcoidosis-related uveitis. Considering that a significant proportion of sarcoidosis shows chronic course of diseases, intravitreal dexamethasone implant injection could be one possible option to relieve intraocular inflammation.
|